SCHEMBL22799994

SCHEMBL22799994

CC#C[C@H](CC(=O)O)c1ccc(OCCC)cc1

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 19/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21121025 1.00 FFAR1 (0.73) FFAR1
SCHEMBL21121027 1.00 FFAR1 (0.73) FFAR1
SCHEMBL21121141 0.94 FFAR1 (0.73) FFAR1
SCHEMBL22799983 0.94 FFAR1 (0.73) FFAR1
SCHEMBL21121140 0.94 FFAR1 (0.73) FFAR1
SCHEMBL21121431 0.92 FFAR1 (0.70) FFAR1
SCHEMBL22799988 0.92 FFAR1 (0.70) FFAR1
SCHEMBL21121428 0.92 FFAR1 (0.70) FFAR1
SCHEMBL22800018 0.91 FFAR1 (0.68) FFAR1
SCHEMBL21121217 0.91 FFAR1 (0.68) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964938-B2 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists CELON PHARMA S.A. (PL) 2024-04-23 US disclosed
EP-3737470-B9 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS Celon Pharma Sa (PL) 2024-03-13 EP disclosed
CN-111757770-B 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists 赛隆制药股份公司 2023-10-03 CN disclosed
EP-3737470-B1 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS Celon Pharma Sa (PL) 2022-12-14 EP disclosed
US-20200399198-A1 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS CELON PHARMA S.A. (PL) 2020-12-24 US disclosed
CN-111757770-A 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists 赛隆制药股份公司 2020-10-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399198-A1 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS GPR119, FFAR1, GPR65 FFAR1 2/4885
US-11964938-B2 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists GPR119, FFAR1, GPR65 FFAR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.